[1] |
Zheng Y, Fu Y, Zhong Q, et al. The treatment of advanced pulmonary sarcomatoid carcinoma[J]. Future Oncol, 2022, 18(6): 727-738. DOI: 10.2217/fon-2021-1071.
|
[2] |
Gong C, Xiong H, Qin K, et al. MET alterations in advanced pulmonary sarcomatoid carcinoma[J]. Front Oncol, 2022, 12: 1017026. DOI: 10.3389/fonc.2022.1017026.
|
[3] |
Yuan M, Zhu Z, Mao W, et al. Anlotinib combined with anti-PD-1 antibodies therapy in patients with advanced refractory solid tumors: a single-center, observational, prospective study[J]. Front Oncol, 2021, 11: 683502. DOI: 10.3389/fonc.2021.683502.
|
[4] |
Zombori-Tóth N, Kiss S, Oštarijaš E, et al. Adjuvant chemotherapy could improve the survival of pulmonary sarcomatoid carcinoma: a systematic review and meta-analysis[J]. Surg Oncol, 2022, 44: 101824. DOI: 10.1016/j.suronc.2022.101824.
|
[5] |
Ma Y, Li W, Li Z, et al. Immunophenotyping of pulmonary sarcomatoid carcinoma[J]. Front Immunol, 2022, 13: 976739. DOI: 10.3389/fimmu.2022.976739.
|